Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records - 2The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- 3Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- 4Investigating the Advantages of a Bank account: A Complete Aide
- 5Chinese astronauts’ return to Earth delayed over fears spaceship damaged by debris
- Hidden Island Cameras Capture Rare Tasmanian Species for the First Time Ever
- 21 Incredibly Interesting Contemplations To Observe Consistently
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- FDA approves Wegovy pill for weight loss: What to know
- Irish defence minister's trip to Lebanon cancelled
- Hypothermia claims newborn in Gaza and more babies are at risk, doctor says
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Novo Nordisk slashes prices of popular weight loss and diabetes drugs
- 4 Famous Attractions at Disneyland
